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ABSTRACT    26 
Recent medical strategies rely on the search for effective antimicrobials as surface coatings to 27 
prevent and treat infections in humans and animals. Biosurfactants have recently been shown 28 
to have properties as antiadhesive and antibiofilm agents. Sophorolipids in particular are 29 
biosurfactant molecules known to act as therapeutic agents. This study aimed to evaluate 30 
antimicrobial properties of sophorolipids in medical-grade silicone discs using strains of 31 
clinical relevance. Sophorolipids were produced under fed batch conditions, ESI-MS analyses 32 
were carried out to confirm the congeners present in each formulation. Three different 33 
products were obtained SLA (acidic congeners), SL18 (lactonic congeners) and SLV 34 
(mixture of acidic and lactonic congeners) and were tested against Staphylococcus aureus 35 
ATCC 6538, Pseudomonas aeruginosa ATCC 10145 and Candida albicans IHEM 2894. All 36 
three congener mixtures showed a biofilms disruption effect (> 0.1% w/v) of 70%, 75% and 37 
80% for S. aureus, P. aeruginosa and C. albicans, respectively. On pre-coated silicone discs, 38 
biofilm formation of S. aureus was reduced by 75% using SLA 0.8% w/v. After 1.5 h the 39 
inhibition of C. albicans attachment was between 45-56% whilst after 24 h incubation the 40 
percentage of inhibition for the cell attachment increased to 68-70% when using SLA 0.8% 41 
w/v. Finally, in co-incubation experiments SLA 0.05% w/v significantly reduced the ability 42 
of S. aureus and C. albicans to form biofilms and to adhere to surfaces by 90-95% at 43 
concentrations between 0.025-0.1% w/v. In conclusion sophorolipids significantly reduced 44 
the cell attachment of both tested strains which suggests that these molecules could have a 45 
potential role as coating agents on medical grade silicone devices for the preventions of Gram 46 
positive bacteria and yeast infections.  47 
Keywords 48 
Sophorolipids, biofilms, Candida albicans, Staphylococcus aureus, Pseudomonas 49 
aeruginosa, medical-grade silicone.  50 
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1. INTRODUCTION 51 
 52 
It is well known that up to 80% of microbial infections that develop in humans are due to 53 
biofilm development (Römling and Balsalobre, 2012). Biofilm infections are associated with 54 
pathogenic or opportunistic bacteria linked to chronic condition with recurrent or long lasting 55 
infections despite the host's immune response and antibiotic therapy (Hall-Stoodley and 56 
Stoodley, 2009). Biofilms develop preferentially on dead tissues or on inert surfaces, such as 57 
medical devices (Lambe et al., 1991), but may also form on living tissues, as in the case of 58 
endocarditis (Costerton et al., 1999). Therefore, although many biofilm infections develop 59 
slowly and initially produce few symptoms, they represent serious clinical problems because 60 
they promote complex responses by the immune system and act as reservoirs of acute 61 
infections (Donlan and Costerton, 2002). 62 
It is difficult however to evaluate the contribution of biofilms in human disease due to the 63 
lack of criteria to characterize the biofilm-induced pathogenesis (Hall-Stoodley and Stoodley, 64 
2009). About 60-70% of nosocomial infections are due to the implantation of medical devices 65 
to improve the quality of life for patients and to provide better medical care (Darouiche, 66 
2001; Bryers, 2008). The cause of these infections is often attributed to the development of 67 
microbial biofilms on devices, and it has been observed that the onset of an inflammatory 68 
response following implantation can lead to the formation of molecules favouring biofilm 69 
adhesion (Hall-Stoodley et al., 2004). 70 
Almost all surfaces can be colonized by biofilms and practically all medical devices or tissue 71 
engineering constructs are susceptible to colonization and microbial infection (Castelli et al., 72 
2007). Biofilm development is often observed on urinary catheters (Stickler, 2008), central 73 
venous catheters (Petrelli et al., 2006), catheters in the cerebrospinal fluid (Odds, 1988), 74 
cardiac prosthetic valves (Litzler et al., 2007), pacemakers (Kojic and Darouiche, 2004), 75 
endotracheal tubes (Odds, 1988), silicone vocal prostheses (Buijssen et al., 2007), contact 76 
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lenses (Imamura et al., 2008), hip prostheses (Dempsey et al. , 2007) and intrauterine devices 77 
(Chassot et al., 2008). 78 
The colonization of the medical device can lead to tissue damage, systemic infection and 79 
altered device functioning, therefore, once the biofilm has formed it is almost always 80 
necessary to remove the device to eliminate the infection. The elimination of the infected 81 
device and the use of high dose antimicrobial agents for long periods of time are essential for 82 
successful therapy against these infections. The main problem with this approach is the 83 
frequent development of antibiotic resistance (Rodrigues, 2011). Therefore, it is clinically 84 
very important to develop technologies to control the formation and growth of biofilms 85 
(Fracchia et al., 2012). For this reason, medical devices are often coated with antimicrobial 86 
and anti-adhesive agents in order to prevent the adhesion and development of biofilm with a 87 
consequent reduction of infections related to them (von Eiff et al., 2005; Basak et al., 2009). 88 
 89 
Surfactants are amphiphilic molecules that are contained in a significative number of 90 
products in use daily and therefore are part of all aspects of our daily lives. Their properties 91 
make them very useful for many industrial and domestic applications, with a global 92 
production exceeding 13 million tonnes per year (Marchant and Banat, 2012). Interest in the 93 
use of biosurfactants in general is steadily increasing in healthcare associated applications to 94 
reduce infections (Krasowska, 2010) particularly, involving their use in controlling biofilms 95 
formation and/or their disruption. Previous studies have shown that the interaction of 96 
biosurfactants with different surfaces can affect their hydrophobic properties affecting the 97 
microorganism’s adhesion abilities and consequent biofilm formation (Shah et al., 2007). 98 
Sophorolipids showed bactericidal properties when compared to conventional antimicrobial 99 
agents with bacteriostatic effects (Diaz De Rienzo et al., 2015). Previous studies indicating 100 
the anti-adhesive properties of biosurfactants have used pure cultures of microorganisms, 101 
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however, analysis of a typical biofilm reveals predominantly mixed cultures. Additionally, 102 
the nutritional composition of biofilms has been shown to affect the adhesion characteristics 103 
of single and mixed cultures (Zezzi do Valle Gomes and Nitscke, 2012). This work aims 104 
investigate antimicrobial effect of sophorolipids on medical grade silicon material surfaces 105 
using microbial strains of clinical relevance: Candida albicans, Staphylococcus aureus and 106 
Pseudomonas aeruginosa. C. albicans is the most common fungal human pathogen causing 107 
diseases ranging from superficial mucocutaneous infections to life-threatening candidiasis 108 
(Pfaller and Diekema, 2007; Ganguly and Mitchell, 2011). S. aureus and Pseudomonas 109 
aeruginosa are pathogen microorganisms responsible for an important number of clinical 110 
infections, including bacteraemia, and device-related infections among others (Tong et al., 111 

















2. MATERIALS AND METHODS 127 
 128 
2.1 Microorganisms and media 129 
Candida bombicola ATCC 22214 was the microorganism used to produce sophorolipids, it 130 
was stored in nutrient broth with 20% glycerol at -80C until further use. The culture medium 131 
for the production of sophorolipids was glucose/yeast extract/urea (GYU) (Diaz De Rienzo, 132 
et al 2015). Rapeseed oil, was used as a second carbon source, fed at regular intervals to 133 
induce sophorolipid production. Candida albicans IHEM 2894 strain was cultivated in Yeast 134 
Nitrogen Base broth (YNBD) + 50 mM Dextrose and stored at -80C until further use. 135 
Staphylococcus aureus ATCC 6538, was cultivated in Tryptic Soy Broth (TSB) + 1% 136 
glucose (G) and stored at -80C until further use. Pseudomonas aeruginosa ATCC 10145, 137 
was cultivated in Brain Heart Infusion (BHI) + 1% G and stored at -80C until further use. 138 
 139 
2.2 Production of sophorolipids  140 
Crude SL mixtures were obtained as crude extract from fed batch cultivation of C. bombicola 141 
ATCC 22214 (Shah et al., 2005), feeding glucose and oleic acid rather than waste frying oil 142 
at 1.5%, 2% and 4% w/v to induce the production of different congeners. The dry matter 143 
content was classified as SLA (acidic congeners), SL18 (lactonic congeners) and SLV 144 
(mixture of both congeners). Sophorolipids were extracted and partially purified by chemical 145 
extraction (Smyth et al., 2009). For mass analysis, partially purified sophorolipids were 146 
dissolved in methanol and characterised by electrospray ionisation–mass spectrometry (ESI–147 
MS) using a Waters LCT mass spectrometer in negative-ion mode. Data was collected via 148 
direct infusion using a syringe pusher over 0.5/min in methanol. A desolvation temperature of 149 
200ºC was applied together with a Desolvation Gas Flow (L/h) of 694 and a capillary voltage 150 
of 3000V.  151 
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2.3 Medical-grade silicone elastomeric discs preparation. 152 
Medical-grade silicone elastomeric discs (SEDs) of 10 mm in diameter, 1.5 mm in thickness 153 
were used for experiments in 24-well culture tissue plates, each silicone disc was cleaned, 154 
sterilized and conditioned according to Ceresa et al., 2016 with minor modifications. The 155 
discs were sonicated for 5 min at 60 kHz using Elma S30H and rinsed two times with 156 
distillate water. Then, discs were submerged in 20 mL of MeOH, sonicated for 5 min at 60 157 
kHz, rinsed twice and steam sterilized for 15 min at 121°C.  158 
 159 
2.4 Antimicrobial susceptibility of C. albicans, S. aureus and P. aeruginosa biofilm 160 
towards sophorolipids. 161 
C. albicans IHEM 2894 biofilm were formed according to Chandra et al., 2008. Fungal cells 162 
were suspended in Phosphate Buffered Saline (PBS) +10% Fetal Bovine Serum (FBS) and 163 
adjusted up to 1⨯107 CFU/mL. The discs were inoculated with 1mL of the suspension and, 164 
after cell adhesion (1.5 h), were moved into a new 24-well plate in the presence of 1mL of 165 
YNBD +10% FBS and incubated for 24 h at 37°C at 90 rpm to promote the biofilm growth 166 
phase.  167 
S. aureus ATCC 6538 was grown in TSB + 1% G, and the suspension was adjusted up to a 168 
concentration of 1⨯107 CFU/mL. Silicone discs were submerged with 1 mL of bacterial 169 
suspension and incubated for 24 h at 37°C in static conditions as described before.  170 
P. aeruginosa ATCC 10145 was grown in BHI + 1% G, and the suspension was adjusted up 171 
to a concentration of 1⨯106 CFU/mL. Silicone discs were submerged with 1 mL of bacterial 172 
suspension and incubated for 24 h at 37°C and 140 rpm. 173 
Microbial pre-formed biofilms were then treated with different concentrations of SLA and 174 
SL18 ranging from 0.05%-0.4%, of SLV ranging from 0.025%-0.2% and incubated for 24 h 175 
at 37°C. The antimicrobial activity of SLA, SLV and SL18 was evaluated using 3-[4,5-176 
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dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)-based colorimetric assay 177 
(Trafny et al., 2013). Biofilms were washed three times with PBS for removal of non-178 
adherent cells and moved in 1 mL of 0.3% MTT solution supplemented with 0.01% G and 179 
1μM menadione. After 30 min of incubation time at 37°C, formazan crystals were dissolved 180 
with 1ml of DMSO/0.1M glycine buffer (pH 10.2) solution (7:1). From each biofilm, 200µL 181 
were transferred to a new 96-well plate and the absorbance was measured at 570 nm. The 182 
assay was carried out in triplicate and repeated three times for all of SLA, SLV and SL18 183 
concentrations used for the test (n=9).  184 
 185 
2.5 Disruption properties of sophorolipids towards C. albicans, S. aureus and P. 186 
aeruginosa. 187 
2.5.1 Co-Incubation 188 
Silicone discs were submerged in 500µL of C. albicans IHEM 2894 inoculum (2⨯107 189 
CFU/mL in PBS + 20% FBS) and an equal volume of double-concentrated SLA (0.05%), 190 
SL18 (0.05%) and SLV solutions (0.025% and 0.05%) (test groups) or PBS (control group). 191 
After the adhesion phase, discs were placed in a new plate containing 1 mL of YNBD + 10% 192 
FBS + 0%, 0.025%, 0.05%, 0.1% SLs and incubated for 24 h at 37C and 90 rpm.  193 
For S. aureus ATCC 6538, silicone discs were inoculated with an equal volume of a bacterial 194 
suspension (2⨯107 CFU/ml in TSB 2X + 2% G) and SLs (0.05%, 0.1%, 0.2%) or PBS and 195 
incubated at 37°C for 24 h. 196 
For P. aeruginosa ATCC 10145, silicone discs were inoculated with an equal volume of a 197 
bacterial suspension (2⨯106 CFU/ml in BHI 2X + 2% G) and SLs (0.05%, 0.1%, 0.2%) or 198 
PBS and incubated at 37°C for 24 h and 140rpm. 199 
The biofilm biomass was quantified by the crystal violet (0.2%) assay. Biofilms were washed 200 
three times with PBS, air-dried and coloured for 10 min and the absorbance at 570 nm was 201 
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measured. Assays were carried out in triplicate and the experiments were repeated three times 202 
(n=9). 203 
 204 
2.5.2 Pre-coating 205 
Elastomeric discs were dipped in 1 mL of SLs solutions at concentrations ranging from 0.2% 206 
to 0.8% (test groups) or PBS (control group) and incubated for 24 h at 37C and 180 rpm.  207 
In the case of C. albicans, discs were moved into 24-well plates containing 1 mL of 208 
suspension, standardised to 1⨯107 CFU/mL in PBS + 10% FBS. After the adhesion phase, 209 
the discs were transferred into a new plate as described before in the co-incubation section.  210 
In the case of S. aureus, discs were incubated with 1 mL of the bacterial suspension at the 211 
concentration of 1⨯107 CFU/mL at 37°C for 24 h, whilst for P. aeruginosa, discs were 212 
incubated with 1 mL of the bacterial suspension at the concentration of 1⨯106 CFU/mL at 213 
37°C and 140 rpm for 24 h.  214 
The anti-adhesion and anti-biofilm activity of SLs-coated discs were evaluated respectively 215 
after 1.5 h and 24 h using the previously described CV staining method. Assays were carried 216 
out in triplicate and experiments were repeated two times (n=6).  217 
 218 
2.6 SEM Analysis  219 
The effect of SLA, SL18 and SLV on cells of Candida albicans IHEM 2894, Staphylococcus 220 
aureus ATCC 6538 and Pseudomonas aeruginosa ATCC 10145 were evaluated through 221 
SEM according to the method described by Ceresa et al., 2015. Each disc was washed three 222 
times in PBS, fixed in a 2.5% glutaraldehyde solution for 24 h at 4°C, washed twice in 223 
distilled water, dehydrated and dried overnight. SEM analyses were conducted in a FEI 224 




2.7 Statistical Analysis  227 
Statistical analysis was carried out by means of the statistical program R (R Development 228 
Core Team, http//www.R-project.org). ANOVA followed by Tukey’s HSD post-test was 229 
used to compare the effect of different SLA, SL18 and SLV concentrations against C. 230 
albicans IHEM 2894, P. aeruginosa ATCC 10145 and S. aureus ATCC 6538 biofilm 231 






















3. RESULTS AND DISCUSSION 252 
3.1 Fermentation process: Sophorolipids production  253 
Candida bombicola ATCC 22214 was able to produce sophorolipids under aerobic 254 
conditions, on GYU medium at 30°C using oleic acid (as a second carbon source) at different 255 
concentrations after 120 h. The production of sophorolipids starts when the yeast cells enter 256 
in stationary phase once they have been triggered by a high carbon/nitrogen ratio (Davila et 257 
al., 1992). Typically, growth rate is dependent upon the hydrophilic substrate used; in our 258 
study, glucose is the hydrophilic substrate of choice whilst oleic acid was chosen as the 259 
hydrophobic substrate for sophorolipid synthesis. 260 
 261 
Different studies have shown that the use of a second lipidic carbon source helps to increase 262 
the production yield of sophorolipids. Particularly favourable sources include rapeseed oil 263 
and most vegetable oils that are rich in C16-18 fatty acids; these carbon sources are more 264 
favourable to renewable production practices, readily incorporated into the sophorolipid 265 
molecule, and add an additional control over molecular diversity (Saerens et al., 2015; 266 
Delbeke et al., 2016). During SL biosynthesis, the enzyme CYP52M1 catalyses oxygenation 267 
of the fatty acids. The enzyme largely determines the length of the fatty acid chain within the 268 
molecule and has a high specificity towards stearic acid (18 carbons, 0 double bonds, C18:0) 269 
and oleic acid (C18:1) which are then mirrored in the fatty acid model of the sophorolipid 270 
molecule. However, the sophorolipids produced by C. bombicola are not typically pure 271 
compounds but consist of a mixture of molecules with variations in molecular weights, chain 272 
length, position of hydroxylation and differences in the saturation of the fatty acid chain (Van 273 
Bogaert et al., 2007). The organism has a preference to produce lactonic congeners of the 274 
SLs, however they are typically produced as a mixture of different congeners with two major 275 
points of variation: acetylation in the sophorose moiety, and lactonisation (Costa et al., 2018).  276 
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The achievement of such congeners is particularly important when considering the potential 277 
therapeutic applications, since acidic and lactonic SLs have been demonstrated to have 278 
different physicochemical and biological activities. Lactonic SLs for example show higher 279 
antimicrobial, virucide, and anti-cancer activity (Shao et al., 2012), whereas acidic SLs show 280 
higher spermicidal and proinflammatory activity (Shah et al., 2005). The predominance for 281 
the production of the acidic or lactonized form is mostly dependant on the tendency of the 282 
metabolic route, which is affected by the fermentation time and hydrophobic substrate used 283 
(Daniel et al., 1998). In this study, changing the concentration of oleic acid and varying the 284 
fermentation process in terms of time had an effect on the production of different congeners 285 
(Fig. 1). 286 
 287 
ESI–MS analysis of each purified product was carried out, Fig. 1A revealed the presence of a 288 
sophorolipid congener produced by C. bombicola ATCC 22214 when grown in 2% v/v oleic 289 
acid.  A dominant peak in the ESI–MS showed a pseudomolecular ion of m/z 621-622 (Fig. 290 
1A), corresponding to a nonacetylated C18:0 SL.  291 
 292 
Table 1. Identification of sophorolipid analogs based on m/z peaks in negative mode [M- H+] 293 
SL structural forms 𝑚/𝑧 [M- H+] 
Nonacetylated SL of C18:0, acidic form 623 
Diacetylated SL of C16:0, lactonic form 661 
Monoacetylated SL of C18:1, acidic form 663 
Diacetylated SL of C18:2, lactonic form 685 
Diacetylated SL of C18:1, acidic form 705 
 294 
This form has previously been reported (Kasturi and Prabhune, 2013) and it is one of the 295 
acidic congeners; for this study, it has been denominated as SLA for all antimicrobial 296 
experiments carried out. The presence of the different congeners was observed when the 297 
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concentration of oleic acid was changed to 1.5% and 4% v/v. Different peaks were detected 298 
(Fig. 1b) corresponding to different acidic and lactonic congeners (Table 1) (Fig. 1b). For all 299 
the antimicrobial experiments, the product that contains a mixture of acidic and lactonic 300 
congeners was called SLV. The purified product that mainly consisted of the lactonic form of 301 
sophorolipids, on the other hand was designated as SL18. 302 
 303 
 304 
3.2 The effect of acidic SLA, lactonic SL18 and mixed SLV sophorolipids on pre-formed 305 
biofilms on medical-grade silicone elastomeric discs. 306 
The ability of SLA, SL18 and SLV to disrupt biofilms formed by either C. albicans, S. 307 
aureus and P. aeruginosa was tested through the MTT assay. Optical densities at 570 nm of 308 
each microorganism vs individual biosurfactant concentrations are shown in Fig. 2. All 309 
strains tested showed the ability to form biofilms on medical-grade silicone discs under the 310 
conditions described here. The combined effect of all biosurfactants used (concentrations 311 
above 0.1% w/v) on the disruption of S. aureus and P. aeruginosa biofilms was significant. 312 
An average of 75% lower metabolic activity was estimated through the MTT assay, using 313 
NAD (P) H-dependent cellular oxidoreductase enzyme (under the conditions used in this 314 
study) as a reflection of the number of viable cells present (Berridge et al., 2005). However, 315 
analysis of the SEM images revealed a less significant effect, indicating that the biofilm 316 
structure was preserved post-treatment (data not shown). 317 
 318 
The Gram-positive microorganism S. aureus can produce a multi-layered biofilm matrix 319 
representing subpopulations of bacteria embedded within a glycocalyx (Archer et al., 2011). 320 
Infections caused by methicillin resistant S. aureus (MRSA) are a serious problem with a 321 
high occurrence in hospital inpatients and healthcare professionals. Some anti-staphylococcal 322 
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antibiotics are available, although the treatment options for MRSA infections remain limited 323 
due to the increasing occurrence of antibiotic resistant phenotypes (Samadi et al., 2012). 324 
Additional environmental factors such as the selective pressures within the distinct matrix 325 
layers have been shown to further encourage resistance (Xu et al., 2000; Singh et al., 2010) 326 
highlighting the importance of developing effective biofilm disruptor therapies. The thickness 327 
of the biofilms formed by these microorganisms are expected to be more than 400µm 328 
(Costerton et al., 1995), which could be the main reason why disruption mediated by 329 
sophorolipids was not evident through SEM, the 3D structure of the biofilm were still visible 330 
but the cells that formed this structure were metabolically compromised as indicated by the 331 
MTT assay (Fig. 2A). Such bactericidal effect of sophorolipids on mixed cultures of B. 332 
subtillis and Staphylococcus aureus has been reported before (Diaz De Rienzo et al., 2015), 333 
which gives an added value to these molecules for potential biomedical applications.  334 
 335 
P. aeruginosa can form biofilms in different environments and it is the responsible for many 336 
acute and chronical infections, plus it is one of the major nosocomial pathogens in patients 337 
with cystic fibrosis (Chen et al., 2018). The clinical relevance and the relative ease of biofilm 338 
growth has made P. aeruginosa a model organism on biofilm formation studies (Maurice et 339 
al., 2018). There have been progress on the development of new treatments for biofilm 340 
infections produced by P. aeruginosa which involves  the use of cationic antimicrobial 341 
peptides which are found naturally in a wide variety of organisms and constitute a major 342 
component of the innate immune system (Beaudoin, et al., 2018), glycoclusters (Boukerb, et. 343 
Al, 2014), plant extracts (Zameer, et al., 2016), biosurfactants (Diaz De Rienzo et al., 2016) 344 
among others. The treatment of the P. aeruginosa ATCC 10145 biofilms with SLV was the 345 
most effective with a disruption about 75% (Fig. 2B) on medical-grade silicone discs. SLV is 346 
a mixed of lactonic and acidic isomers, and this results confirm those showed before where 347 
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sophorolipids from Ecover® had a bactericidal effect against cells of P. aeruginosa ATCC 348 
15442 within a period on 30 min (Diaz De Rienzo et al., 2016). 349 
 350 
C. albicans usually produces biofilms composed of multiple cell types (i.e., round, budding 351 
yeast-form cells; oval pseudohyphal cells; and elongated, cylindrical hyphal cells) encased in 352 
an extracellular matrix (Chandra et al., 2001; Dominic et al., 2007). These microorganisms 353 
are responsible for at least 15% of the total sepsis cases acquired within a clinical setting, 354 
moreover, their occurrence accounts for the fourth most common determinant of bloodstream 355 
infections in clinical settings, and the predominant fungal species isolated from medical 356 
device infections (Wenzel, 1995; Wisplighoff, 2004), therefore highlighting the importance 357 
of the disruption on medical-grade silicone discs.  358 
 359 
The disruptive effects of SLA, SLV (at all the concentrations tested) and SL18 (at 360 
concentrations above 0.1% w/v) on C. albicans IHEM 2894 biofilms showed 80% inhibition 361 
(evaluated as an indirect measure of the metabolic activity) (Fig. 2C).  To our knowledge, this 362 
study is the first reporting sophorolipids as antimicrobial disruptors of C. albicans biofilms. 363 
The recent emergence of lipopeptide biosurfactants as a new generation of agents with anti-364 
adhesive and antimicrobial properties with enhanced biocompatibility provide potential 365 
commercial applications in the pharmaceutical and biomedical fields (Cameotra and Makkar, 366 
2004; Fracchia et al., 2015; Ceresa et al., 2016). This work shows the potential use of lactonic 367 
sophorolipids as disruptive agents at concentrations as low as 0.05% w/v.  368 
 369 
 370 
3.3 Antimicrobial properties of SLA, SL18 and SLV on C. albicans, P. aeruginosa and S. 371 
aureus  372 
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The antimicrobial effect of SLA, SL18 and SLV (at different concentrations) on all the 373 
microbial strains were evaluated under co-incubation experimental conditions (Fig. 3). All 374 
the treatments resulted in a significant reduction of the total adherent cells and biofilm 375 
biomass from C. albicans and S. aureus compared to the controls, whilst no effect was 376 
detected against cells of P. aeruginosa (data not shown). SLA (at 0.05% and 0.1% w/v) 377 
showed the highest impact in preventing the attachment of both S. aureus and C. albicans 378 
cells, although lactonic SLs have been reported to have better surface tension lowering and 379 
antimicrobial activity as compared to the acidic form (de Oliveira et al., 2015). Under the 380 
conditions of the present study, the acidic form displayed superior antimicrobial activity. The 381 
findings presented here are thought to be mainly due to the hydrophilic properties of the SLs 382 
in solution enabling the formation of smaller globular micelles, which therefore interact more 383 
closely with the microbial cells. 384 
 385 
The antimicrobial effect of sophorolipids on S. aureus cells have been reported before (Diaz 386 
De Rienzo et al., 2015) where sophorolipids (a congeners mix) at 5% v/v induced disruption 387 
on mature maximal biofilms of B. subtilis BBK006 as well as a mixed culture containing B. 388 
subtilis BBK006 and S. aureus. In both cases, the cells exhibited an outpouring of 389 
cytoplasmic contents due to the presence of the intracellular enzyme malate dehydrogenase, 390 
indicating the interaction of sophorolipids with the cellular membrane increasing 391 
permeability (Dengle-Pulate et al., 2014). In this study, the concentration used was 50 times 392 
lower (0.05% w/v) and the inhibition on the biofilm biomass was up to 90% with no visible 393 
cytoplasmic content (Fig 3A).   394 
 395 
To our knowledge, there is no report on the antimicrobial effect of sophorolipids on the 396 
inhibition on the biofilm biomass of C. albicans when co-incubated with concentrations 397 
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between 0.025-0.1% w/v of sophorolipids concentration. In this study, the experiments were 398 
carried out at two different times: 1.5 h and 24 h (fig. 3B and 3C respectively). In general, the 399 
highest reduction in the cell attachment (>95%) was achieved after 24h of incubation. 400 
Different studies showed the effect of different biosurfactants against C. albicans biofilms 401 
(Ceresa et al., 2016), where the effect of a lipopeptide AC7 BS (0.5-3 mg/mL) was evaluated 402 
on C. albicans 40, C. albicans 42 and C. albicans IHEM 2894, resulting in a significant 403 
reduction of the total adherent cells and biofilm biomass (with a maximum inhibition of 68% 404 
at 2mg/ml). Additionally, the influence of lipopeptides from Bacillus amyloliquefaciens strain 405 
on polystyrene plates was shown to inhibit C. albicans biofilm formation between 46-100%, 406 
depending on the concentration and on Candida strains (Rautela et al., 2014). 407 
 408 
3.4 Anti-adhesive properties of SL18 on biofilms formed by C. albicans, P. aeruginosa 409 
and S. aureus  410 
The anti-adhesive properties of SL18 were tested on cells of S. aureus, P. aeruginosa (after 411 
24h) and C. albicans (at 1.5 h and after 24 h). Concentrations from 0.2-0.8% w/v were tested, 412 
and total biofilm biomass was quantified (Fig. 4). Pre-coating experiments revealed the 413 
biofilm formation and adhesion properties of S. aureus and C. albicans were progressively 414 
reduced as a function of increased SL18 concentrations, with SL18 0.8% showing the 415 
greatest inhibitory effect towards cell attachment to the silicone discs. On the other hand, 416 
under the same conditions no anti-adhesive effect was shown on cells of P. aeruginosa. 417 
Biosurfactants can disrupt phospholipid membranes and affect the cell-to-cell surface 418 
interactions by decreasing hydrophobicity and interfering with the cell deposition and 419 
microbial adhesion processes (Rodrigues et al., 2006). 420 
Certain structural analogues of SLs have been shown in previous studies to inhibit conidia 421 
germination in the fungus Glomerella cingulata (Kitamoto and Isoda, 2002). SLs have also 422 
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demonstrated an inhibitory effect on the growth of some Gram-positive bacteria, which 423 
include B.acillus subtilis, Micrococcus luteus, Neisseria mucosa and Mycobacterium rubrum 424 
(Elshikh et al., 2017) and Streptococcus oralis, as well as Gram-negative bacteria including 425 
Escherichia coli, Serratia marcescens (de Oliveira et al., 2015) when deposited onto 426 
polystyrene surfaces. Antimicrobial activity of lactonic sophorolipids (98% lactonic SL 427 
mixture composed of C18:1 and C18:0) was previously reported for action against 428 
Propionibacterium acnes, and demonstrates inhibitory action at 2.4 mg/ml on films of pectin- 429 
and alginate-based SL composites (Ashby et al., 2011). 430 
 431 
In this study, S. aureus ATCC 6538 cells were incubated for 24h (Fig. 4A), and a 75% 432 
inhibition on the cell attachment was visible when SL18 (0.8% w/v) was used, in comparison 433 
with the controls where the silicone discs were not pre-treated using biosurfactants. Previous 434 
studies have shown pre-treatment of catheters using minocycline and rifampin significantly 435 
decreases the incidence of central line-associated bloodstream infections caused by S. aureus 436 
in a medical intensive care unit in a manner that was independent and complimentary to 437 
precautionary measures for infection control (Ramos et al., 2011). However, this is the first 438 
time that pre-treatment of medical grade silicone discs with SL18 has shown a high 439 
percentage of inhibition after 24h incubation.  440 
 441 
In the assays with C. albicans, analysis was carried out at 1.5 and 24 h incubation (Fig. 4B 442 
and 4C). At 1.5 h the C. albicans cells were in the initial phase of adhesion and the yeast cell 443 
counts were very low compared with the 24 h incubation (as can be seen through the SEM 444 
images).  After 1.5 h the inhibition was in the range of 45-56% whilst after 24 h the 445 
percentage of inhibition on the cell attachment increased (using 0.8% w/v) was in the range 446 
of 68-70%. These results are in contrast to previous reports (Ceresa et al., 2016), where the 447 
medical silicone discs treated with 2 mg/mL the lipopeptide biosurfactant AC7 BS were able 448 
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to significantly reduced the cell attachment (C. albicans) at a range of 57.7–62.0 % at 1.5 h 449 
and in a range of 45.9–47.6 % after 24 h of incubation. This is a clear indication that the 450 
inhibition at different stages depends on the disc treatment, referring to the nature of the 451 
antimicrobial agent. 452 
 453 
4. CONCLUSIONS 454 
Our results indicate that sophorolipids (acidic, lactonic or mixed congener form) are able to 455 
reduce the biofilm biomass that is able to form 3D mature films on medical grade silicone 456 
discs under the conditions tested in this study. These results also display strong anti-adhesive 457 
properties with up to 75% inhibition in the pre-treated group. However, further investigations 458 
are needed to explore the effects of lower concentrations, as well as studies of cytotoxicity to 459 
be able to extend the use of sophorolipids as antimicrobial molecules with commercial impact 460 
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FIGURE CAPTIONS 738 
 739 
Figure 1. A. ESI-MS analysis of SLA. Spectrum of partially purified extracts from fermented cells of C. 740 
bombicola. Oleic acid 2% was induced after 48 h and 120 h. B. ESI-MS analysis of  SLV. Spectrum of partially 741 




Figure 2. Sophorolipids activity against S. aureus 24 h pre-fromed biofilm on medical grade silicone discs (A), 744 
P. aeruginosa 24 h pre-fromed biofilm (B) and C. albicans 24 h pre-fromed biofilm (C) evaluated by the MTT 745 
assay. Three different products were used: SLA, SL18 and SLV at different concentrations. 746 
 747 
Figure 3. Activity of sophorolipids on co-incubation experiments. Biofilms formed by (A) S. aureus 24 h and  748 
(B) C. albicans 1.5 h and (C) C. albicans 24 h evaluated by crystal violet assay. Scanning electron micrographs 749 
showed the control cells (left) and tretaed with SLA 0.1% w/v (right). The magnification bar for image A is 10 750 
μm, and for images B and C is 20 μm. 751 
 752 
Figure 4. Activity of SL18 adhered to medical grade silicone discs on biofilm formation of (A) S. aureus 24 h 753 
and (B) C. albicans 1.5 h and (C) C. albicans 24 h evaluated by crystal violet assay. Scanning electron 754 
micrographs showed the control cells and tretaed with SL18 0.8% (w/v). The magnification bar for image A is 755 
10 μm, and for images B and C is 50 μm. 756 
